10-Q: INVO Fertility Reports Q1 2025 Results, Navigates Strategic Shift

INVO Fertility reports its Q1 2025 financial results while strategically refocusing on its fertility business and planning the divestiture of its majority stake in NAYA Therapeutics.

Summary

• INVO Fertility, Inc. reported its financial results for the first quarter ended March 31, 2025.
• The company is strategically refocusing on its fertility business and plans to divest a majority stake in NAYA Therapeutics.
• Revenue for Q1 2025 was approximately $1.6 million, consistent with $1.6 million in Q1 2024.
• The cost of revenue for Q1 2025 was approximately $1.0 million, compared to $0.9 million for Q1 2024.
• Selling, general, and administrative expenses for Q1 2025 were approximately $2.6 million, compared to $1.4 million for Q1 2024.
• Research and development expenses for Q1 2025 were approximately $266 thousand, compared to $5 thousand for Q1 2024.
• The company recorded an impairment loss of approximately $14.6 million in Q1 2025 related to the NTI acquisition.
• The net loss for Q1 2025 was approximately $17.4 million, compared to $1.6 million for Q1 2024.
• As of March 31, 2025, the company had approximately $0.8 million in cash.
• The company completed a public offering in January 2025, raising net proceeds of approximately $8.7 million.
• The company is settling a dispute with Dr. Elizabeth Pritts with payments totaling $5 million.
• The company is addressing defaults on a senior secured convertible promissory debenture and seeking to amend the debenture.
• The company is in the process of improving its internal control over financial reporting to remediate material weaknesses.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is strategically refocusing and raised capital, it also reported a significant net loss and impairment loss, and faces ongoing legal and financial challenges.

Positives

• The company completed a public offering in January 2025, raising net proceeds of approximately $8.7 million.
• The company is settling a dispute with Dr. Elizabeth Pritts with payments totaling $5 million.
• The company is addressing defaults on a senior secured convertible promissory debenture and seeking to amend the debenture.

Negatives

• The company recorded a significant impairment loss of $14.6 million related to the NTI acquisition.
• The net loss for Q1 2025 was approximately $17.4 million, compared to $1.6 million for Q1 2024.
• The company is addressing defaults on a senior secured convertible promissory debenture and seeking to amend the debenture.
• The company is in the process of improving its internal control over financial reporting to remediate material weaknesses.

Risks

• The company has a history of net losses and may require additional funding to meet its liquidity needs.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company is subject to legal proceedings and claims, including a dispute with Dr. Elizabeth Pritts and a complaint from a former NTI employee.
• The company is addressing defaults on a senior secured convertible promissory debenture and seeking to amend the debenture.
• The company is in the process of improving its internal control over financial reporting to remediate material weaknesses.

Future Outlook

The company expects its fertility operations to make further operational progress in 2025 and is actively pursuing additional acquisitions of established and profitable IVF clinics. The company also plans to expand the distribution of the INVOcell to third-party fertility clinics. The company expects to complete the divestiture of its majority interest in NAYA Therapeutics in the second quarter of 2025.

Industry Context

The global ART marketplace is a large and growing, multi-billion-dollar industry across the world as increased infertility rates, greater patient awareness and improving financial incentives, such as insurance and governmental assistance, continue to drive demand. The global bispecific antibodies market is projected to witness over 40% compound annual growth rate and reach over $80 billion by 2030.

Comparison to Industry Standards

• The current market leader, CD38 targeting monoclonal antibody, Darzalex (daratumumab) reached $8 billion in global sales in 2022.
• The new BCMA targeting bispecific antibody from Pfizer, Elrexfio, was approved in August 2023.

Legal Proceedings

• Dr. Elizabeth Pritts and the Pritts Trust filed a complaint against the Company and its subsidiaries.
• Seline Miller, a former employee of NAYA Therapeutics, filed a complaint against NAYA Therapeutics.

Stakeholder Impact

• The company's strategic shift and financial performance may impact shareholders.
• The settlement with Dr. Pritts and the resolution of other legal proceedings may impact the company's financial stability.
• The company's ability to continue as a going concern may impact employees and other stakeholders.

Next Steps

• The company plans to complete the divestiture of its majority interest in NAYA Therapeutics in the second quarter of 2025.
• The company seeks to finalize and execute the Settlement Agreement and related documentation in the second quarter of 2025.
• The company seeks to finalize and execute the definitive amended debenture in the near term.
• The company will continue to take additional steps necessary to remediate the material weaknesses described above.

Key Dates

Keywords

INVO Fertility, NAYA Therapeutics, financial results, Q1 2025, fertility, IVF, INVOcell, acquisition, divestiture, impairment, public offering, legal proceedings, convertible debenture, internal control